Castle Biosciences, Inc.

NASDAQ:CSTL

Medical - Diagnostics & Research

Healthcare
$33.38 +0.20%

+$0.04 today

Market cap
$1.03B
Beta
1.02
P/E (TTM)
-47.3
EPS (TTM)
-$0.43
52W Low $14.59High $44.28

Volume 0.38M

Average 0.37M

CSTL Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Castle Biosciences, Inc.NASDAQ: CSTL

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation declines year over year

Q1 FY2026 stock-based compensation of $9.78M fell 12.6% year over year, behind the -8.9% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 14.3% from the prior quarter. Over 3 fiscal years it compounded at +8.1% a year.

Context

  • Stock-based compensation amounted to 13.3% of revenue in FY2025, down 1.8 pp from a year earlier.
  • Stock-based compensation increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -12.6% toward the trailing-twelve-month pace of -8.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$9.78M-14.3% QoQ
Last fiscal yearDec 2025
$45.89M-8.8% YoY
LTMMar 2026
$44.49M-8.9% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-12.6%——
1 year-8.8%——
3-year CAGR+8.1%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
45.89M USD
Year-over-year change
-8.8%
4-year CAGR
+20.5%

Stock-Based Compensation vs competitors

How CSTL compares with its peers on the latest reported figures

  • CSTL's LTM Mar 2026 stock-based compensation of $44.49M is the 3rd largest of the 8 companies compared; the peer median is $28.16M.
  • Its year-over-year change of -8.9% is the 5th highest of 8, against a peer median of -4.5%.
  • Stock-based compensation amounts to 13.1% of revenue for CSTL, versus a peer median of 4.5%.
CSTL Competitors Peer median
Stock-Based Compensation for CSTL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GHGuardant Health, Inc.LTM Sep 2026$210.96M +32.4%+20.6%16.5%
VCYTVeracyte, Inc.LTM Jun 2026$48.51M +20.3%+17.7%8.6%
CSTLCastle Biosciences, Inc.LTM Mar 2026$44.49M -8.9%+8.1%13.1%
MYGNMyriad Genetics, Inc.LTM Mar 2026$32.2M -31.9%-2.6%3.9%
NEONeoGenomics, Inc.LTM Jun 2026$28.16M -29.2%+18.8%3.7%
PSNLPersonalis, Inc.LTM Mar 2026$9.76M -4.5%-21.4%15.1%
BDSXBiodesix, Inc.LTM Mar 2026$4.28M -13.8%-11.4%4.5%
MDXHMDxHealth S.A.FY2025$2.21M +28.2%+36.6%2.0%
FRNMFreenome, Inc. Common stock—— ———
Peer median (excluding CSTL) $28.16M-4.5%+17.7%4.5%

Competitors are the stored peer set for CSTL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(31.29M)(67.14M)(57.47M)18.25M(24.16M)
Depreciation & Amortization3.41M10.54M12.33M16M40.77M
Deferred Income Tax(8.74M)(1.88M)(223K)1.4M(6.23M)
Stock-Based Compensation21.74M36.32M51.22M50.32M45.89M
Change in Working Capital(4.1M)(7K)(6.63M)(14.13M)13.6M
Accounts Receivables(4.63M)(6.22M)(14.93M)(12.64M)6.88M
Inventory327K(1.68M)(3.96M)(193K)(2.14M)
Accounts Payables(182K)582K5.71M(4.37M)3.08M
Other Working Capital384K7.31M6.56M3.08M5.79M
Other Non-Cash Items0(19.5M)(4.86M)(6.97M)(5.53M)
Operating Cash Flow(18.98M)(41.66M)(5.63M)64.87M64.35M
Capital Expenditures(3.48M)(5.63M)(13.62M)(28.33M)(36.02M)
Acquisitions (Net)(63.18M)(26.97M)018K(18.73M)
Purchases of Investments0(134.69M)(189.08M)(205.73M)(188.71M)
Sales of Investments00186.5M183.9M190.73M
Other Investing Activities10K742K13K0(7.64M)
Investing Cash Flow(66.66M)(166.55M)(16.18M)(50.14M)(60.37M)
Debt Repayment(8K)(122K)(142K)9.9M(115K)
Common Stock Issued0002.02M2.21M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities5.43M1.64M(2.16M)(5.78M)(9.05M)
Financing Cash Flow5.42M1.52M(2.3M)6.14M(6.96M)
Effect of Forex Changes00000
Net Change in Cash(80.22M)(206.69M)(24.11M)20.87M(2.98M)
Free Cash Flow(22.47M)(47.29M)(19.25M)36.54M28.33M

Castle Biosciences, Inc.

NASDAQ:CSTL

Intrinsic Alpha fair value

Locked

Current Price

$33.38

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.